Name of respondent: Steve Simmonds |
Are you responding on behalf of an organisation? Yes. |
If so please give the name Community Pharmacy Wales (CPW) |
Address: 3rd Floor, 2 Caspian Point, Pier Head Street, Cardiff Bay, CARDIFF CF10
4DQ |
Telephone number: 029 2044 2076 |
Would you be willing to give oral evidence to the Committee? Yes |
If the evidence you give below is your personal view, rather then that of an organisation, please state whether or not you are willing for your evidence to be published by putting a X in the appropriate box below: The
information provided is the view of CPW |
I am content for my evidence to be published Yes |
| I am not content for my evidence to be published N/A |
| 3 |
What are your views on the complexity of commissioning services? Is the process hampered by the involvement of the local health boards, cancer networks and Health Commission Wales? How could it simplified? |
Response |
CPW have for some time been concerned by the high degree of variance in the quality of commissioning at LHB level and feels that part of the answer lies in the extension of the remit of the regional/ health economy commissioning groups, proposed in the Designed
to Deliver strategies, to cover the commissioning of primary care services. There is little evidence on the ground that nGMS funding is being made available to other professions and growing evidence that community pharmacy enhanced services are continually being
bumped to the back of the commissioning queue. CPW are also disappointed with the willingness of WAG to actively support the introduction of National Enhanced Services and Directed Enhanced Services for community pharmacy. |
| 4 |
What evidence is there of the value of screening and immunisation? |
Response |
CPW are unable to comment on the value of screening and immunisation in relation to cancer care. CPW do however feel that the potential of the community pharmacy network to become involved in population screening is regularly overlooked. In a recent review of
bowel cancer services we recommended that the distribution of testing kits should be carried out through the community pharmacy network. Community pharmacies are the most accessible of all of the health outlets and are ideally placed to support population screening
and the provision of public health advice. |
| 5 |
What are the barriers to the NHS in Wales keeping abreast of, and responding to, developing technologies and therapies? How might these barriers be overcome? |
| Response |
CPW is not able to comment on this section. |
| 6 |
How can the NHS and the voluntary sector work together more effectively to deliver services? |
| Response |
CPW is not able to comment on this section. |
| 7 |
How can the collection and use of data on where the terminally ill spend their last weeks or months be improved better to inform service provision for those people? |
| Response |
CPW is not able to comment on this section |
| 8 |
There are a number of issues around prescribing and the cost of drugs: |
| 8(i) |
What should be done and by whom to reduce continued prescribing of inappropriate drugs? |
Response |
A 'Medicines Use Review’ service has been introduced as part of the New Community Pharmacy Contract and a clinical medication review service is available for commissioning as an enhanced service. If supported by specialist training this Enhanced Service
could be used to review patient’s cancer medication on a domiciliary visit by a community pharmacist. This would reduce the incidents of inappropriate prescribing and improve patient concordance. Independent
Prescribing rights have recently been extended to community pharmacists and over time this will provide community pharmacists with the opportunity to become more involved in the management of patients suffering from chronic conditions. This will facilitate community
pharmacists in becoming an integral part of a multidisciplinary response to the management of cancer patients. |
| 8(ii) |
Should people who are prepared to pay privately for drugs not available to them on the NHS, be able to do so without having to become private patients and having to pay for all their treatment? |
Response |
CPW feels that the act of prescribing by a GP should be an act of confirmation that the medicines being planned for the patient are in their opinion both necessary and appropriate. CPW believes that all medication that will be of benefit to cancer patients,
or will improve their quality of life, should be available to the patient. If the NHS in Wales is unable to make this medication available to patients as part of the NHS service then it should facilitate access to these medicines by patients who are able or
willing to cover the cost of the medicines themselves with the minimum of additional barriers and bureaucracy. |
| 8(iii) |
Do doctors, pharmacists and other health professionals have adequate access to independent advice and guidance on the prescribing of drugs? |
Response |
Community pharmacists have access to independent advice through many sources including an in-house journal, NICE Guidelines, the Wales Medicines Partnership and access to the Medicines Information Service provided by the trusts. Recent moves to provide community
pharmacists with access to the Electronic Library for Health have further improved their access to independent information although we have recently been made aware that planned funding for this element has been withdrawn. With such a wide range of resources
available to prescribers many prescribers will need training on how to judge the appropriateness of the information that is available and how to best access the information. |